Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PRS-344/S095012 |
Synonyms | |
Therapy Description |
PRS-344/S095012 is a fusion protein comprised of 4-1BB-specific anticalin proteins linked to an anti-PD-L1 antibody, which may increase antitumor immune response and inhibit tumor growth (PMID: 35121624). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRS-344/S095012 | PRS344/S095012|PRS 344/S095012 | PD-L1/PD-1 antibody 117 | PRS-344/S095012 is a fusion protein comprised of 4-1BB-specific anticalin proteins linked to an anti-PD-L1 antibody, which may increase antitumor immune response and inhibit tumor growth (PMID: 35121624). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05159388 | Phase Ib/II | PRS-344/S095012 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 0 |